The provocative findings from this study open several avenues for future research. First, there is a need for larger, multicenter, prospective studies that can validate the association of Lp(a) with specific plaque characteristics using more precise and quantitative imaging techniques. Investigating the longitudinal impact of elevated Lp(a) on plaque progression and ASCVD events, particularly focusing on the role of noncalcified plaque, will provide crucial insights.Second, exploring the interplay between Lp(a), inflammation, and coronary microvascular disease (CMD) can uncover novel mechanisms and therapeutic targets. CMD, often underdiagnosed, poses significant cardiovascular risks, and understanding its relationship with Lp(a) could lead to better risk stratification and management, especially in women who are disproportionately affected.Additionally, role of other CCTA-based novel radiomics should be explored, like the role of pericoronary adipose tissue (PCAT) as a marker of inflammation in relation to elevated Lp(a) warrants further exploration. Advanced imaging techniques assessing PCAT could enhance our understanding of the inflammatory milieu associated with high Lp(a) levels and its contribution to ASCVD risk.Last, the development and evaluation of Lp(a)-lowering therapies should be closely monitored using advanced imaging modalities like CCTA to assess their impact on plaque stabilization and regression. Such studies could pave the way for personalized treatment approaches that consider both traditional risk factors and novel markers like Lp(a).The intriguing and sometimes paradoxical findings of this study underscore the complexity of cardiovascular risk assessment and the need for continued innovation in both diagnostic and therapeutic strategies. As our understanding of Lp(a) evolves, so too must our approach to managing the risks it presents.
PR
Dr. Patricia Rodriguez Lozano
Cardiology · Advanced Cardiac ImagingUniversity of Virginia Health SystempatriciaCharlottesville, VA, USA